Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EGFRvIII-CAR T Cells for Leptomeningeal Glioblastoma
NCT05063682Phase 1Unknown
- Start
- May 2020
- Primary completion
- Oct 2023
- Modality
- CAR-T Cells
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of EGFRvIII-CAR T cells in glioblastoma (GBM). Primary endpoints: Incidence of adverse events at 10 years and Overall survival at 12 months. Status: unknown.
02
Drugs
EGFRvIII-CAR T cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT05063682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05063682.